株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

マールブルグ出血熱 - パイプライン製品の分析

Marburg Hemorrhagic Fever - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 321901
出版日 ページ情報 英文 77 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
マールブルグ出血熱 - パイプライン製品の分析 Marburg Hemorrhagic Fever - Pipeline Review, H2 2016
出版日: 2016年07月20日 ページ情報: 英文 77 Pages
概要

マールブルグ出血熱は希少ですが急性の感染症で、ヒトおよびヒト以外の霊長類に感染します。発熱、頭痛、悪寒、下痢、胃痛、体重減少などが症状です。

当レポートでは、マールブルグ出血熱に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

マールブルグ出血熱の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究所別

パイプライン製品の概要

  • 臨床段階の製品
  • 初期段階の製品

開発中の製品:企業別

調査中の製品:大学/研究所別

治療薬の開発に従事している企業

  • GlaxoSmithKline plc
  • Immunovaccine, Inc.
  • Integrated BioTherapeutics, Inc.
  • Sarepta Therapeutics, Inc.
  • Tekmira Pharmaceuticals Corp.
  • Vaxart, Inc

治療薬の評価

  • 単独療法の製品
  • 併用療法の製品
  • 標的別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • AVI-7288
  • ebola + marburg vaccine
  • marburg vaccine
  • marburg vaccine
  • marburg virus vaccine
  • Monoclonal Antibodies for Ebola and Marburg Infections
  • Monoclonal Antibody for Marburg Virus
  • panfilovirus (multivalent) vaccine
  • TKM-Marburg

最新のパイプライン情報

開発休止中のプロジェクト

製品開発のマイルストーン

  • 注目のニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8266IDB

Summary

Global Markets Direct's, 'Marburg Hemorrhagic Fever - Pipeline Review, H2 2016', provides an overview of the Marburg Hemorrhagic Fever pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Marburg Hemorrhagic Fever, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Marburg Hemorrhagic Fever and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Marburg Hemorrhagic Fever
  • The report reviews pipeline therapeutics for Marburg Hemorrhagic Fever by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Marburg Hemorrhagic Fever therapeutics and enlists all their major and minor projects
  • The report assesses Marburg Hemorrhagic Fever therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Marburg Hemorrhagic Fever

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Marburg Hemorrhagic Fever
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Marburg Hemorrhagic Fever pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Marburg Hemorrhagic Fever Overview
  • Therapeutics Development
    • Pipeline Products for Marburg Hemorrhagic Fever - Overview
    • Pipeline Products for Marburg Hemorrhagic Fever - Comparative Analysis
  • Marburg Hemorrhagic Fever - Therapeutics under Development by Companies
  • Marburg Hemorrhagic Fever - Therapeutics under Investigation by Universities/Institutes
  • Marburg Hemorrhagic Fever - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Marburg Hemorrhagic Fever - Products under Development by Companies
  • Marburg Hemorrhagic Fever - Products under Investigation by Universities/Institutes
  • Marburg Hemorrhagic Fever - Companies Involved in Therapeutics Development
    • Arno Therapeutics, Inc.
    • BioCryst Pharmaceuticals, Inc.
    • GeoVax Labs, Inc.
    • GlaxoSmithKline Plc
    • Integrated BioTherapeutics, Inc.
    • Johnson & Johnson
    • NanoViricides, Inc.
    • Profectus BioSciences, Inc.
    • Sarepta Therapeutics, Inc.
  • Marburg Hemorrhagic Fever - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (Ebola + Marburg) (monovalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (Ebola + Marburg) (trivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (Ebola + Marburg) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (Ebola [Sudan, Zaire] + Marburg) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • 1-E703 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antibodies for Ebola and Marburg Viral Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AR-12 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ARD-5 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AVI-7288 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BCX-4430 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FDX-000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GOVXE-301 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GOVXE-302 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • imatinib mesylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Marburg vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies for Ebola and Marburg Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody for Marburg Virus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit Glycoprotein for Ebola and Marburg Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nilotinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Ebola and Marburg Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Ebola and Marburg Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Alpha-Glucosidase I and II for Viral Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Marburg Hemorrhagic Fever - Dormant Projects
  • Marburg Hemorrhagic Fever - Discontinued Products
  • Marburg Hemorrhagic Fever - Product Development Milestones
    • Featured News & Press Releases
      • Jul 22, 2015: Sarepta Therapeutics Announces New England Journal of Medicine Publication of Phase I Clinical Data of Marburg Drug Candidate, AVI-7288, Supporting Safety of the PMOplus platform
      • Feb 10, 2014: Sarepta Therapeutics Announces Positive Safety Results from Phase I Clinical Study of Marburg Drug Candidate
      • Sep 17, 2013: BioCryst Awarded Contract by the National Institute of Allergy and Infectious Diseases to Develop BCX4430 for the Treatment of Marburg Virus Disease
      • May 07, 2013: Sarepta Therapeutics Initiates Dosing In Phase I Multiple Ascending Dose Study Of Drug For Treatment Of Marburg Virus
      • Mar 04, 2013: Sarepta Therapeutics's Marburg Drug Shows High Survival Rates After Intramuscular Delivery In Non-Human Primates
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Marburg Hemorrhagic Fever, H2 2016
  • Number of Products under Development for Marburg Hemorrhagic Fever - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Marburg Hemorrhagic Fever - Pipeline by Arno Therapeutics, Inc., H2 2016
  • Marburg Hemorrhagic Fever - Pipeline by BioCryst Pharmaceuticals, Inc., H2 2016
  • Marburg Hemorrhagic Fever - Pipeline by GeoVax Labs, Inc., H2 2016
  • Marburg Hemorrhagic Fever - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Marburg Hemorrhagic Fever - Pipeline by Integrated BioTherapeutics, Inc., H2 2016
  • Marburg Hemorrhagic Fever - Pipeline by Johnson & Johnson, H2 2016
  • Marburg Hemorrhagic Fever - Pipeline by NanoViricides, Inc., H2 2016
  • Marburg Hemorrhagic Fever - Pipeline by Profectus BioSciences, Inc., H2 2016
  • Marburg Hemorrhagic Fever - Pipeline by Sarepta Therapeutics, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Marburg Hemorrhagic Fever - Dormant Projects, H2 2016
  • Marburg Hemorrhagic Fever - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Marburg Hemorrhagic Fever, H2 2016
  • Number of Products under Development for Marburg Hemorrhagic Fever - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top